EGFR Amplification and sensitizing mutations correlate with survival in lung adenocarcinoma patients treated with erlotinib (MutP-CLICaP)

Vista sencilla de ítem
dc.contributor.authorRuiz-Patiño, Alejandro
dc.contributor.authorCastro, Christian David
dc.contributor.authorRicaurte, Luisa María
dc.contributor.authorCardona-Mendoza, Andrés Felipe
dc.contributor.authorRojas Puentes, Leonardo
dc.contributor.authorZatarain-Barrón, Zyanya Lucia
dc.contributor.authorWills, Beatriz
dc.contributor.authorReguart, Noemí
dc.contributor.authorCarranza Isaza, Hernán
dc.contributor.authorVargas Báez, Carlos Alberto
dc.contributor.authorOtero, Jorge
dc.contributor.authorCorrales, Luis
dc.contributor.authorMartín, Claudio
dc.contributor.authorArchila, Pilar
dc.contributor.authorRodríguez Ariza, July Katherine
dc.contributor.authorÁvila Coy, Jenny Mireya
dc.contributor.orcidCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.contributor.orcidCarranza Isaza, Hernán [0000-0002-3593-7405]
dc.contributor.orcidVargas Báez, Carlos Alberto [0000-0002-6076-8260]
dc.contributor.orcidRojas Puentes, Leonardo [0000-0002-7865-5424]
dc.contributor.orcidRodríguez Ariza, July Katherine [0000-0003-1168-595X]
dc.contributor.orcidÁvila Coy, Jenny Mireya [0000-0002-2968-7980]
dc.date.accessioned2020-05-18T06:45:08Z
dc.date.available2020-05-18T06:45:08Z
dc.date.issued2018
dc.description.abstractenglishBackground Non-small cell lung cancer (NSCLC) has a 5-year survival of 5–16%. Epidermal growth factor receptor (EGFR) mutations, in most cases, confer sensitivity to EGFR tyrosine kinase inhibitor (TKI) therapy. Nonetheless, it is still unclear why clinical outcomes vary among patients with identical EGFR mutations. The amplification of the EGFR gene (EGFRamp) may play a significant role. Objective Compare the complete (CR) and partial response (PR) rates, overall survival (OS), and progression-free survival (PFS) in Hispanic patients with lung adenocarcinoma treated with erlotinib with EGFR mutations (L858R or exon 19 deletion [Del19]) with and without concomitant EGFRamp. Patients and Methods Seventy-two EGFR-positive lung adenocarcinoma patients of Hispanic origin, who underwent first-line treatment with erlotinib, were evaluated for EGFRamp by fluorescence in situ hybridization (FISH). The clinical outcomes were analyzed according to EGFR mutations and EGFRamp status. Results 30.6% of samples showed EGFRamp, more frequently present in patients with Del19 (p = 0.05). Patients with EGFRamp had a longer PFS (in months) [(28.5, 95% CI 22.3–34.6) vs. (11.0, 95% CI 8.2–16.7); p = 0.002] and OS [(37.8, 95% CI 30.9–44.7) vs. (27.1, 95% CI 12.8–41.3); p = 0.009] than those without. EGFRamp significantly influenced the response to erlotinib (p = 0.0001). EGFRamp+/Del19 had a longer OS, 37.8 (95% CI 31.0–44.6), compared to EGFRamp+/L8585R, 27.5 (95% CI 12.4–42.5) (p < 0.001) and longer PFS (p = 0.043). Conclusion Among Hispanic patients, EGFRamp was present in 30% of patients with EGFR mutations. EGFR mutations and EGFRamp are associated with better OS, PFS, CR, and PR to erlotinib and, hence, could aid in the correct selection of patients that benefit from EGFR TKI treatment.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1007/s11523-018-0594-x
dc.identifier.issn1776-2596
dc.identifier.urihttps://hdl.handle.net/20.500.12495/2904
dc.language.isoeng
dc.publisherSpringerspa
dc.publisher.journalTargeted Oncologyspa
dc.relation.ispartofseriesTargeted Oncology, 1776-2596, Vol 13, Num 5, 2018, pag 621-629spa
dc.relation.urihttps://link.springer.com/article/10.1007%2Fs11523-018-0594-x
dc.rights.creativecommons2018
dc.rights.localAcceso cerradospa
dc.subject.decsGenes erbB-1spa
dc.subject.decsGenes supresoresspa
dc.subject.decsNeoplasias glandulares y epitelialesspa
dc.titleEGFR Amplification and sensitizing mutations correlate with survival in lung adenocarcinoma patients treated with erlotinib (MutP-CLICaP)spa
dc.title.translatedEGFR Amplification and sensitizing mutations correlate with survival in lung adenocarcinoma patients treated with erlotinib (MutP-CLICaP)spa
dc.typearticlespa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localartículospa

Archivos

Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos